153 related articles for article (PubMed ID: 19342756)
1. Response variability and the role of platelet function testing.
Gurbel PA; Mahla E; Antonino MJ; Tantry US
J Invasive Cardiol; 2009 Apr; 21(4):172-8. PubMed ID: 19342756
[No Abstract] [Full Text] [Related]
2. A new method of representing drug-induced platelet inhibition: better description of time course, response variability, non-response, and heightened activity.
Gurbel PA; Bliden KP
Platelets; 2003; 14(7-8):481-3. PubMed ID: 14713517
[No Abstract] [Full Text] [Related]
3. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
Raju NC; Eikelboom JW; Hirsh J
Nat Clin Pract Cardiovasc Med; 2008 Dec; 5(12):766-80. PubMed ID: 18957959
[TBL] [Abstract][Full Text] [Related]
4. Monitoring platelet function to reduce the risk of ischemic and bleeding complications.
Price MJ
Am J Cardiol; 2009 Feb; 103(3 Suppl):35A-39A. PubMed ID: 19166711
[TBL] [Abstract][Full Text] [Related]
5. Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness.
Armstrong PC; Dhanji AR; Truss NJ; Zain ZN; Tucker AT; Mitchell JA; Warner TD
Thromb Haemost; 2009 Oct; 102(4):772-8. PubMed ID: 19806265
[TBL] [Abstract][Full Text] [Related]
6. The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests.
Elsenberg EH; van Werkum JW; van de Wal RM; Zomer AC; Bouman HJ; Verheugt FW; Berg JM; Hackeng CM
Thromb Haemost; 2009 Oct; 102(4):719-27. PubMed ID: 19806258
[TBL] [Abstract][Full Text] [Related]
7. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
[TBL] [Abstract][Full Text] [Related]
8. Response to aspirin and clopidogrel monitored with different platelet function methods.
Mani H; Linnemann B; Luxembourg B; Kirchmayr K; Lindhoff-Last E
Platelets; 2006 Aug; 17(5):303-10. PubMed ID: 16928602
[TBL] [Abstract][Full Text] [Related]
9. [Technological and biopharmaceutical aspects. Antiplatelet agents for oral administration].
Breitkreutz J
Pharm Unserer Zeit; 2009; 38(4):330-7. PubMed ID: 19572353
[No Abstract] [Full Text] [Related]
10. Prasugrel offers consistent platelet control in appropriate patients requiring treatment.
Aalbers J
Cardiovasc J Afr; 2011; 22(2):107, 109. PubMed ID: 21556460
[No Abstract] [Full Text] [Related]
11. Resistance to antiplatelet resistance is it justified?
Steinhubl SR; Charnigo R; Moliterno DJ
J Am Coll Cardiol; 2005 Jun; 45(11):1757-8. PubMed ID: 15936601
[No Abstract] [Full Text] [Related]
12. Variability of response to antiplatelet therapy: what should we do next?
Shantsila E; Lip GY
Fundam Clin Pharmacol; 2009 Feb; 23(1):19-22. PubMed ID: 19267768
[No Abstract] [Full Text] [Related]
13. Aspirin and clopidogrel resistance-a myth or reality: an update.
Gupta S; Gupta MM
Indian Heart J; 2008; 60(3):245-53. PubMed ID: 19240315
[No Abstract] [Full Text] [Related]
14. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
[TBL] [Abstract][Full Text] [Related]
15. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
Am J Cardiol; 2006 Jan; 97(1):38-43. PubMed ID: 16377281
[TBL] [Abstract][Full Text] [Related]
16. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
Wiviott SD
Cardiol Clin; 2008 Nov; 26(4):629-37. PubMed ID: 18929236
[TBL] [Abstract][Full Text] [Related]
17. Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel.
van Werkum JW; Topcu Y; Postma S; Kelder JC; Hackeng CM; ten Berg JM; Verheugt FW
Thromb Haemost; 2008 Mar; 99(3):637-9. PubMed ID: 18327417
[No Abstract] [Full Text] [Related]
18. Proposal of a "gradient model" to evaluate residual platelet activity on antiplatelet therapy: A pilot study.
Lelli N; Rizkallah R; Ferrari P; Pedretti S; Cariani E; Trenti T
Thromb Res; 2017 Feb; 150():19-21. PubMed ID: 27992784
[No Abstract] [Full Text] [Related]
19. Triple antiplatelet therapy for clopidogrel resistance with stent malapposition: a case report.
Ding FH; Zhang Q; Zhang RY; Hu J; Shen J; Zhao LP; DU R; Zhang X; Shen WF
Chin Med J (Engl); 2009 Sep; 122(18):2186-8. PubMed ID: 19781309
[No Abstract] [Full Text] [Related]
20. [Diagnosis, causes, relevance of a complex phenomenon. Resistance to aspirin and clopidogrel].
Mani H; Lindhoff-Last E
Pharm Unserer Zeit; 2009; 38(4):342-50. PubMed ID: 19572355
[No Abstract] [Full Text] [Related]
[Next] [New Search]
